Statins and fibrinogen
1998; Elsevier BV; Volume: 351; Issue: 9113 Linguagem: Inglês
10.1016/s0140-6736(05)79471-x
ISSN1474-547X
Autores Tópico(s)Diabetes, Cardiovascular Risks, and Lipoproteins
ResumoAs the manufacturers of atorvastatin (Lipitor), we at Parke-Davis/Warner Lambert would like to respond to Anthony Wierzbicki and colleagues' letter.1Wierzbicki AS Lumb PJ Semra YK Crook MA Effect of atorvastatin on plasma fibrinogen.Lancet. 1998; 331: 351Google Scholar They refer to uncontrolled data on fibrinogen in 95 patients treated with atorvastatin. We have reviewed all fibrinogen data from controlled trials in about 900 patients and that no significant changes in fibrinogen in those treated with atorvastatin. Assessments of fibrinogen in a broad range of patients at 4, 8, 16, and 52 weeks failed to demonstrate any significant increase in fibrinogen at any time-point or at any dose of atorvastatin. Bakker-Arkema et al2Bakker-Arkema RG Davidson MH Goldstein RJ et al.Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.JAMA. 1996; 275: 128-133Crossref PubMed Google Scholar reported no meaningful effect on fibrinogen. In their study 20 and 80 mg doses reduced fibrinogen by 1·5% over 4 weeks (data on file). Davidson et al3Davidson M McKenney J Stein E et al.Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolaemia.Am J Cardiol. 1997; 79: 1475-1481Summary Full Text Full Text PDF PubMed Scopus (229) Google Scholar reported a slight but not significant increase in fibrinogen or atorvastatin and lovastatin at 52 weeks. They also assessed fibrinogen at 16 weeks and observed a slight decrease in fibrinogen for both drugs and a slight increase for placebo. In an unpublished randomised trial of 534 patients comparing atorvastatin with simvastatin, pravastatin, lovastatin, and fluvastatin, no significant difference in the change in fibrinogen levels was seen between any of the treatment groups. Dujovne et al4Dujovne CA Overhiser RW Harris WS et al.Changes in haemorrheology and atherothrombotic parameters by improving serum lipids in atorvastatin-treated hyperlipidaemics. In: 66th Congress of the European Atherosclerosis Society (Florence, July 13–17, 1996). Giovanni Lorenzini Medical Foundation, Houston1996Google Scholar found a 1% increase in 22 patients at the 80 mg dose of atorvastatin after 12 weeks of treatment. These trials confirm the lack of a clinically important effect on fibrinogen with atorvastatin or other statins. Statins and fibrinogenAuthors' reply Full-Text PDF
Referência(s)